Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2012 Oct;48(10):633-44. doi: 10.1358/dot.2012.48.10.1860768.

Axitinib, a new therapeutic option in renal cell carcinoma.

Author information

  • 1University of Colorado School of Medicine, Division of Medical Oncology, Denver, Colorado 80045, USA.


Axitinib is a small-molecule protein-tyrosine kinase receptor inhibitor specifically targeting this family of receptors, in addition to platelet-derived growth factor receptor and proto-oncogene c-Kit. Improved knowledge of kidney cancer development, and specifically mutations in the VHL gene, has supported the targeting of angiogenesis pathways. Axitinib is the most recently approved agent for use in metastatic renal cell carcinoma. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical activity of this agent, and describe its place in the current treatment of renal cell carcinoma.

Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk